Onyx Pharmaceuticals (NASDAQ: [[ticker:ONXX]]), the Emeryville, CA-based cancer drug developer, said today that sorafenib (Nexavar) failed to reach its main goal of helping people live longer with non-small cell lung cancer in a study of about 900 patients. The drug is currently marketed to treat kidney cancer, and a type of liver cancer known as hepatocellular carcinoma. The study unveiled today, called Nexus, evaluated people getting their first round of treatment for lung cancer. Onyx and Bayer have other studies ongoing against later stages of lung cancer.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
